Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Aykut Ozdarendeli
 -- 2845 2023-10-08 03:52:17 |
2 layout & references
Sirius Huang
 Meta information modification 2845 2023-10-08 10:34:26 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Ozdarendeli, A. Immune Response to Crimean–Congo Hemorrhagic Fever Virus Infection. Encyclopedia. Available online: https://encyclopedia.pub/entry/49922 (accessed on 06 September 2024).
Ozdarendeli A. Immune Response to Crimean–Congo Hemorrhagic Fever Virus Infection. Encyclopedia. Available at: https://encyclopedia.pub/entry/49922. Accessed September 06, 2024.
Ozdarendeli, Aykut. "Immune Response to Crimean–Congo Hemorrhagic Fever Virus Infection" Encyclopedia, https://encyclopedia.pub/entry/49922 (accessed September 06, 2024).
Ozdarendeli, A. (2023, October 08). Immune Response to Crimean–Congo Hemorrhagic Fever Virus Infection. In Encyclopedia. https://encyclopedia.pub/entry/49922
Ozdarendeli, Aykut. "Immune Response to Crimean–Congo Hemorrhagic Fever Virus Infection." Encyclopedia. Web. 08 October, 2023.
Immune Response to Crimean–Congo Hemorrhagic Fever Virus Infection
Edit
This entry is adapted from the peer-reviewed paper 10.3390/diagnostics13162708

Crimean–Congo hemorrhagic fever virus (CCHFV), a member of the Nairoviridae family and Bunyavirales order, is transmitted to humans via tick bites or contact with the blood of infected animals. It can cause severe symptoms, including hemorrhagic fever, with a mortality rate between 5 to 30%. CCHFV is classified as a high-priority pathogen by the World Health Organization (WHO) due to its high fatality rate and the absence of effective medical countermeasures. 

Crimean–Congo hemorrhagic fever virus hemorrhagic fever immune response

1. Introduction

Crimean–Congo hemorrhagic fever virus (CCHFV) is a member of the genus Orthonairovirus in the family Nairoviridae and the order Bunyavirales [1][2]. The viral genome is composed of three negative-sense RNA segments: small (S), medium (M), and large (L). The S segment encodes the nucleoprotein (NP), while the M segment encodes the glycoprotein precursor (GPC), which later forms mature Gn, Gc, and several nonstructural proteins such as mucin, GP38, and NSm [3][4][5][6]. The L segment encodes the L protein responsible for viral RNA synthesis, which includes the RNA-dependent RNA polymerase (RdRp) and an ovarian tumor (OTU) protease domain (for which the L protein is crucial for viral RNA synthesis) and includes the RNA-dependent RNA polymerase (RdRp) and an OTU protease domain that may aid in evading the host’s innate immunity (Figure 1a,b) [7][8][9].
Figure 1. Crimean–Congo hemorrhagic fever virus (CCHFV) virion structure and CCHFV vaccine platforms. (a) CCHFV virion contains three single-stranded RNA segments with a negative-sense orientation. Nucleoprotein (NP) and RNA-dependent RNA polymerase (RdRp; L protein) protect the RNA by enclosing the RNA segments and forming ribonucleoprotein complexes (RNPs). Once the ribonucleoprotein (RNP) complexes are formed, they are surrounded by a protective envelope that originates from the membrane of the host cell. This envelope is coated with specialized glycoproteins known as Gn and Gc. (b) CCHFV consists of three genomic segments—small (S), medium (M), and large (L). The S segment is responsible for encoding the NP within one open reading frame, while the small non-structural protein (NSs) is encoded in an opposite-sense open reading frame. The M segment is quite intricate, as it encodes a glycoprotein precursor (GPC) that undergoes processing by host proteases. This processing results in the production of a GP160/85 domain, which is then further processed into a mucin-like domain (MLD) and GP38. Additionally, the M segment encodes the Gn and Gc glycoproteins, as well as the medium non-structural protein (NSm). The L segment of CCHFV, which is distinctively larger than other bunyaviruses, encodes for the viral RNA-dependent RNA polymerase (RdRP) and an ovarian tumor-like protease (OTU) at its N terminus. (c) A diagrammatic representation of different CCHFV vaccine platforms. The diagram was created with Adobe Illustrator.
It was initially detected in Soviet soldiers in Crimea during the 1940s. In the 1960s, a virus with similar symptoms to the Crimean virus was discovered in the Belgian Congo (currently known as the Democratic Republic of the Congo). Further studies revealed that both viruses were antigenically identical, leading to the virus being named CCHFV [10][11][12][13]. CCHFV circulates within an enzootic cycle that involves ticks and vertebrates [14][15][16]. Although CCHFV has been isolated in multiple tick species, Hyolamma ticks serve as the host and biological vector for CCHFV due to its extensive geographical range, which closely correlates with the distribution of CCHF cases [17][18]. Ticks can transmit CCHFV vertically from one generation to the next, transovarially from one developmental stage to another, sexually from males to females during copulation, or through cofeeding from one tick to other ticks feeding on the same non-viremic host [19][20][21][22]. CCHFV infects a wide range of both wild and domestic animals. However, infections in these animals are typically asymptomatic, but they exhibit viremia for more than five days, which helps the maintenance of CCHFV in nature [14][17][18][19][20][21][22].
CCHFV is found in a vast geographic region, from western China to Africa, the Middle East, Spain, and the Balkans [23][24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39][40]. Turkey has been experiencing CCHF epidemics since 2002, with the number of cases increasing significantly in recent years [41][42][43][44][45]. Similarly, some Balkan countries have reported regular cases of the disease [46]. CCHF was first reported in Spain in 2016, although tick surveillance studies had already shown the presence of CCHFV in the area [36]. This suggests a shift in the main vector’s geographic distribution, as there were no previous reports of autochthonous human cases in Spain [47][48][49]. Ticks primarily disperse over long distances only through their hosts [50]. Therefore, changes in tick populations are primarily associated with bird migrations or expansions of host populations. The geographical spread of tick populations is concerning as infected ticks transported to non-endemic areas can spread the disease to humans [48][51][52][53]. Furthermore, uninfected ticks introduced to a new area may establish populations that can sustain the virus after its introduction. The expansion of CCHF’s geographic distribution is also driven by several factors, including global warming, the increasing of human mobility, and human activities such as deforestation and agricultural growth, leading to more people coming into contact with infected ticks and animals [54][55][56][57]. Transporting livestock is a widespread practice across the world, and its contribution to the spread of CCHF cannot be overlooked. The movement of animals across borders or the transportation of infected ticks from endemic regions can initiate new CCHF outbreaks in non-endemic regions [58][59][60][61][62].
Human beings are regarded as accidental hosts of the CCHFV. Humans become infected through tick bites or exposure to crushed infected ticks during agricultural activities. Another significant source of infection is the blood of infected agricultural animals, which can be viremic but not display any symptoms of disease [14][17]. Nosocomial transmission contributes to the spread of CCHFV, leading to higher fatality rates compared to those resulting from tick bites. Several cases of nosocomial outbreaks have been linked to infected blood or needle-stick injuries during patient care [63][64][65][66][67]. CCHFV infection in humans can cause mild to severe symptoms, including high fever, malaise, myalgia, and gastrointestinal distress, typically after a short incubation period of about a week. Severe cases can result in hemorrhagic disease with a fatality rate ranging from 5 to 30%, often due to disseminated intravascular coagulopathy, shock, and/or multi-organ failure [63][64][65][67]. Due to its high fatality rate, widespread vector, and the absence of effective medical countermeasures for prevention and treatment, CCHFV is classified as a high-priority pathogen by the World Health Organization (WHO) [68].

2. Immune Response to CCHF Infection

Effective control of CCHFV infection in the host relies on immune responses from both the innate and adaptive systems. The innate immune system acts as the first line of defense against viruses by limiting viral entry, translation, replication, and assembly. Additionally, it facilitates the identification and elimination of infected cells, as well as the development of adaptive immunity through coordination and acceleration. Type 1 interferons (IFN-α/β) are produced by the host’s innate immune response against viruses. These responses are rapid and efficient, and they can be generated and secreted by all mammalian cells. These immunomodulators facilitate the expression of antiviral proteins, inhibit cell proliferation, and help regulate apoptosis [69][70][71].
The innate immune response is stimulated by CCHFV, leading to the production of IFNs and interferon-stimulated genes (ISGs). Andersson et al. conducted in vitro studies that confirmed the antiviral effect of IFN on CCHFV. The studies highlighted a substantial reduction of vRNA levels in cells treated with IFN, emphasizing the crucial role of IFN in controlling CCHFV replication [72]. Hawman et al. recently created a novel model using type I interferon-deficient mice, whereby infection with the human clinical isolate strain Hoti resulted in progressive illness characterized by several days of overt clinical signs [73]. This model also demonstrated the induction and release of IFNs, the subsequent upregulation of ISGs, and the involvement of the host’s innate immune response to CCHFV [74]. Bente et al. confirmed the crucial role of IFN in combating CCHFV using a STAT-1 KO mouse model, where STAT1 is a central component of IFN signaling pathways [75]. In 2012, CCHFV-infected IFN1-deficient mice (IFNAR−/−) exhibited clinical symptoms resembling CCHF, whereas wild-type mice remained asymptomatic, highlighting the importance of IFN1 in preventing CCHFV infection [76]. IFN is also crucial in controlling infections and preventing diseases in animals, even those with compromised adaptive immune systems.
Lindquist et al. demonstrated the temporary suppression of the immune response in various mouse strains (including wild-type and those with impaired adaptive immunity such as NOD/SCID, Prf1−/− and Rag2−/−) by utilizing an anti-IFNAR1 monoclonal antibody (mAb) [77]. IFN responses play a significant role in determining disease severity. Studies indicated that polymorphisms in toll-like receptor genes (TLR7, 8, 9, and 10) are associated with increased illness severity in Turkish CCHF patients, thereby emphasizing the crucial role of TLRs as an immune-sensing pathway in controlling the virus [78][79]. Despite IFNs being crucial in the host’s immune response, CCHFV utilizes various strategies to evade and counteract the innate immune response. These include removing the 5’ triphosphate group from the viral genome to avoid RIG-I recognition, delaying IRF-3 activation through the particle recognition pathway, and downregulating NF-kappaB activation [80][81][82]. Additionally, studies have shown that CCHFV can suppress the body’s innate immune system by encoding an ovarian tumor-related deubiquitinase (OTU) domain. This domain deubiquitinates proteins involved in the body’s signaling pathways, thereby inhibiting innate immune responses including the antiviral response mediated by ISG15 modifications. In addition, the OTU domain has both de-ISGylation and deubiquitinase activity, which are important for viral pathogenesis [8][83].
Apoptosis can serve as a significant innate response to viral infections. It is a critical process involved in viral infections, as its suppression or induction determines the level of infection spread. Viruses can either inhibit host cell apoptosis, which is a defense mechanism against infections, to ensure their survival or on the contrary promote apoptosis to eliminate uninfected immune cells and facilitate viral spread [84][85]. As with many other viruses, CCHFV also has the ability to regulate apoptosis. CCHF infection induces TNF-α and FasL-mediated apoptosis in cell culture [86]. CCHFV NP inhibits caspase 3 and caspase 9 activation, prevents apoptosis initiated by BAX, and curtails the release of cytochrome c from mitochondria [87]. However, the specific point in the intrinsic apoptosis pathway where NP disrupts activation is yet to be determined. Despite the CCHFV NP inhibiting activation in the intrinsic pathway of apoptosis, the CCHFV NSs, a cryptic ambisense product of the NP, has been found to disrupt mitochondrial membrane potential, inducing apoptosis by activating caspase 3/7 and cleaving poly ADP-ribose polymerase. Furthermore, the presence of a conserved DEVD motif in the virus’ NP that can be cleaved by host caspase 3 implies a regulatory role in the virus’s life cycle [88].
Pro-inflammatory cytokines and chemokines, which are produced by various immune cells in response to viral infections, play a crucial role in the innate immune response against viral pathogens [89]. When a virus enters the body, immune cells such as macrophages and dendritic cells recognize it through pattern recognition receptors (PRRs) on their surface. These PRRs identify pathogen-associated molecular patterns (PAMPs) that are unique to the invading virus. Upon recognition of viral PAMPs, immune cells release pro-inflammatory cytokines [89][90]. While pro-inflammatory cytokines and chemokines are critical for the innate immune response to viral infections, excessive or uncontrolled release of these molecules can lead to tissue damage and inflammatory disease [91][92]. CCHFV initially targets immune cells such as dendritic cells, macrophages, and monocytes [93]. This results in the production of pro-inflammatory cytokines, including TNF-α, IL1, IL6, IL8, IL-12, IFN-γ, MCP-1, and MIP-1b [94]. Pro-inflammatory responses in severe or fatal diseases can lead to vascular dysfunction, disseminated intravascular coagulation (DIC), organ failure, and shock [95]. Increased levels of TNF-α, IL-8, IL-9, IL-15, IP-10, and MCP-1 are associated with disease severity and negative outcomes in patients from Turkey, Albania, and Kosovo [17][94][95][96][97]. Researchers have also found that the secretion of sTREM-1 by myeloid cells enhances inflammatory responses during CCHF virus infection, though it remains to be empirically demonstrated how excessive levels of these inflammatory agents may drive pathogenic processes [98][99].
While innate immunity serves as the initial protective response against CCHFV infection, a potent adaptive immune response is also essential for effective control of the infection. Anti-CCHFV IgM and IgG antibodies are detectable within 7–9 days from symptom onset [100][101][102]. IgG antibodies typically peak during the second to third week and can remain for up to 3 years. In contrast, IgM titers decline within 3 weeks and become undetectable between 3–5 months after disease onset. The absence of serum antibodies has been linked to higher mortality rates in CCHF patients, suggesting that antibodies may provide protection against fatal CCHFV infection [97][100]. Kaya et al. assessed serial antibody responses on 31 patients with CCHF, 11 of which were fatal cases. The study revealed that all surviving patients had a positive IgG titer within 9 days of onset, whereas none of the fatal cases showed such a response at the same timepoint [103]. In a study conducted on 24 patients with 43 samples, it was observed that quantitative IgG levels and viral loads had a correlation, and none of the fetal patients developed positive IgG titers. Only one sample from nine survivors taken less than nine days after the onset of the disease showed positive IgG titers. There was no correlation between death or viral load and IgM positivity [104]. In a study involving 46 confirmed cases of acute CCHFV infection in Kosovo, it was discovered that there was no correlation between the presence of IgM antibodies and clinical classification. Furthermore, only 5 out of the 34 patients who survived the disease exhibited IgG antibodies [95].
Neutralizing antibodies (NAbs) usually appear by day 10 of the illness. They are usually found at low levels in CCHF survivors, but are undetectable in fatal cases of CCHF [97][100]. This suggests that antibodies may play a crucial role in protecting individuals from lethal CCHFV infections. As of now, the study has revealed that mAbs and neutralizing mAbs specific to CCHFV have exclusively been derived from mice [105]. Among the isolated antibodies, three Gc-specific NAbs have demonstrated the ability to neutralize multiple strains of the virus [105][106]. However, despite their cross-neutralizing activity, these NAbs have not been effective in providing protection against CCHF in experiments conducted on mouse models. These epitopes are not associated with the production of NAbs that contribute to the immune response against CCHF. Three Gc-specific NAbs cross-neutralize various strains but are ineffective in protecting mouse models of CCHF [105][106]. Studies have shown that although mAbs targeting pre-Gn and/or GP38 lack neutralizing activity, they can still provide pre-exposure protection in mice [105][106][107][108]. These findings suggest that non-NAbs may also have the ability to protect against CCHF through other mechanisms besides neutralization, as evidenced by their ability to confer protection in fatal CCHF challenges. The GP38-targeting mAbs effectiveness in providing protection depends on complement activity. This finding suggests that the antibody’s effector functions, such as complement-mediated lysis and phagocytosis, play a crucial role in protecting against CCHFV [107]. However, a recent study illustrated the efficacy of bispecific antibodies (bsAbs) by incorporating variable domains from wide NAbs to boost their antiviral efficacy. The study found one bsAb to be particularly effective as it provided therapeutic protection against CCHFV with a single dose [109]. Thus, it is currently unclear whether there is any relationship between the neutralization antibody responses and positive disease outcomes.
Several studies have found a strong relationship between a high viral load and fatality rate, with some identifying a viral load of ≥108 copies/mL as a significant predictor of fatality [63][95][104][110]. While a reduction in CCHF viral load has been connected with the presence of antibodies in clinical infections, the production of antibodies is not always linked to the clearance of the virus. During the first week of infection, viral loads generally decrease irrespective of IgG levels, indicating the critical role of cellular immunity [95][104]. A study conducted with STAT1-deficient mice showed that CD4+ and CD8+ T cells were activated early against CCHFV infection [75]. Studies on infected mice have demonstrated that T cells play a critical role in controlling CCHFV infection. They limit the virus’s spread and prevent further infection by producing antiviral cytokines upon rapid activation [73][74].
The maintenance of CCHFV-specific T cells for an extended period after infection suggests that memory T cells may offer long-term immunity against the virus, responding rapidly to future exposure and serving as a lasting defense [111]. The study on a DNA vaccine highlights the significance of a TH1 response for effective protection [112]. It was shown that CD8+ T cell responses in human survivors lasted for 13 years after acute infection. Most T cell epitopes were found on the NP, but there were two instances of reactivity to GC-derived peptides. None of the epitopes were considered immunodominant [113]. Lindquist et al. found that an IFN blockade antibody treatment in mice effectively controlled CCHFV through adaptive immune responses, specifically cytolytic T cell activity, while avoiding liver damage, which is a common issue caused directly by CCHFV [77]. The removal of CD4+ or CD8+ T cells in mice infected with the virus resulted in a higher mortality rate, highlighting the indispensability of these cells in survival [74]. Hawman et al. also found that the absence of CD4 T cells eliminated the host’s IFN-γ response and blocking IFN-γ signaling led to lethality in IFNAR−/− mice, suggesting that cellular immunity and type II IFN may control the CCHFV infection. Despite the existing research on the role of the adaptive immune response in CCHFV infection, further studies are needed to determine the immune responses and their effector functions essential for protection.

References

  1. Abudurexiti, A.; Adkins, S.; Alioto, D.; Alkhovsky, S.V.; Avšič-Županc, T.; Ballinger, M.J.; Bente, D.A.; Beer, M.; Bergeron, É.; Blair, C.D.; et al. Taxonomy of the order Bunyavirales: Update 2019. Arch. Virol. 2019, 164, 1949–1965.
  2. Garrison, A.R.; Alkhovsky, S.V.; Avšič-Županc, T.; Bente, D.A.; Bergeron, É.; Burt, F.; Di Paola, N.; Ergünay, K.; Hewson, R.; Kuhn, J.H.; et al. ICTV virus taxonomy profile: Nairoviridae. J. Gen. Virol. 2020, 101, 798–799.
  3. Carter, S.D.; Surtees, R.; Walter, C.T.; Ariza, A.; Bergeron, É.; Nichol, S.T.; Hiscox, J.A.; Edwards, T.A.; Barr, J.N. Structure, function, and evolution of the Crimean-Congo hemorrhagic fever virus nucleocapsid protein. J. Virol. 2012, 86, 10914–10923.
  4. Guo, Y.; Wang, W.; Ji, W.; Deng, M.; Sun, Y.; Zhou, H.; Yang, C.; Deng, F.; Wang, H.; Hu, Z.; et al. Crimean–Congo hemorrhagic fever virus nucleoprotein reveals endonuclease activity in bunyaviruses. Proc. Natl. Acad. Sci. USA 2012, 109, 5046–5051.
  5. Sanchez, A.J.; Vincent, M.J.; Nichol, S.T. Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J. Virol. 2002, 76, 7263–7275.
  6. Sanchez, A.J.; Vincent, M.J.; Erickson, B.R.; Nichol, S.T. Crimean-Congo hemorrhagic fever virus glycoprotein precursor is cleaved by furin-like and SKI-1 proteases to generate a novel 38-kilodalton glycoprotein. J. Virol. 2006, 80, 514–525.
  7. Honig, J.E.; Osborne, J.C.; Nichol, S.T. Crimean–Congo hemorrhagic fever virus genome L RNA segment and encoded protein. Virology 2004, 321, 29–35.
  8. Scholte, F.E.M.; Zivcec, M.; Dzimianski, J.V.; Deaton, M.K.; Spengler, J.R.; Welch, S.R.; Nichol, S.T.; Pegan, S.D.; Spiropoulou, C.F.; Bergeron, É. Crimean-Congo hemorrhagic fever virus suppresses innate immune responses via a ubiquitin and ISG15 specific protease. Cell Rep. 2017, 20, 2396–2407.
  9. Perng, Y.C.; Lenschow, D.J. ISG15 in antiviral immunity and beyond. Nat. Rev. Microbiol. 2018, 16, 423–439.
  10. Chumakov, M.P. 30 Years of investigation of Crimean hemorrhagic fever (Russian). Proc. Inst. Polio. Viral Enceph. USSR Acad. Med. Sci 1974, 22, 5–18.
  11. Butenko, A.M.; Chumakov, M.P.; Rubin, V.N.; Stolbov, D.N. Isolation and investigation of Astrakhan strain (“Drozdov”) of Crimean hemorrhagic fever virus and data on serodiagnosis of this infection. Mater. 15 Nauchn. Sess. Inst. Polio Virus Entsefalitov (Moscow) 3, 88–90 (in Russian; in English, NAMRU3-T866). In: Whitehouse CA. Crimean-Congo hemorrhagic fever. Antivir Res. 2004, 64, 145–160.
  12. Chumakov, M.P.; Butenko, A.M.; Shalunova, N.V.; Mart’ianova, L.I.; Smirnova, S.E.; Bashkirtsev, I.N.; Zavodova, T.I.; Rubin, S.G.; Tkachenko, E.A.; Karmysheva, V.I.A. Novye dannye o viruse-vozbuditele krymskoĭ gemorragicheskoĭ likhoradki . Vopr Virusol 1968, 13, 377.
  13. Simpson, D.I.; Knight, E.M.; Courtois, G.; Williams, M.C.; Weinbren, M.P.; Kibukamusoke, J.W. Congo virus: A hitherto undescribed occurring In Africa. I. Human isolations—Clinical notes. East Afr. Med. J. 1967, 44, 86–92.
  14. Whitehouse, C.A. Crimean-Congo hemorrhagic fever. Antivir. Res. 2004, 64, 145–160.
  15. Vorou, R.; Pierroutsakos, I.N.; Maltezou, H.C. Crimean-Congo hemorrhagic fever. Curr. Opin. Infect. Dis. 2007, 20, 495–500.
  16. Gargili, A.; Estrada-Peña, A.; Spengler, J.R.; Lukashev, A.; Nuttall, P.A.; Bente, D.A. The role of ticks in the maintenance and transmission of Crimean-Congo hemorrhagic fever virus: A review of published field and laboratory studies. Antivir. Res. 2017, 144, 93–119.
  17. Ergönül, Ö. Crimean-Congo haemorrhagic fever. Lancet Infect. Dis. 2006, 6, 203–214.
  18. Mourya, D.T.; Yadav, P.D.; Shete, A.; Majumdar, T.D.; Kanani, A.; Kapadia, D.; Chandra, V.; Kachhiapatel, A.J.; Joshi, P.T.; Upadhyay, K.J.; et al. Serosurvey of Crimean-Congo hemorrhagic fever virus in domestic animals, Gujarat, India, 2013. Vector Borne Zoonotic Dis. 2014, 14, 690–692.
  19. Shepherd, A.J.; Swanepoel, R.; Cornel, A.J.; Mathee, O. Experimental studies on the replication and transmission of Crimean-Congo hemorrhagic fever virus in some African tick species. Am. J. Trop. Med. Hyg. 1989, 40, 326–331.
  20. Gordon, S.W.; Linthicum, K.J.; Moulton, J.R. Transmission of Crimean-Congo hemorrhagic fever virus in two species of Hyalomma ticks from infected adults to cofeeding immature forms. Am. J. Trop. Med. Hyg. 1993, 48, 576–580.
  21. Logan, T.M.; Linthicum, K.J.; Bailey, C.L.; Watts, D.M.; Moulton, J.R. Experimental transmission of Crimean- Congo haemorrhagic fever virus by Hyalomma truncatum Koch. Am. J. Trop. Med. Hyg. 1989, 40, 207–212.
  22. Okorie, T.G. Comparative studies on the vector capacity of the different stages of Amblyomma variegatum Fabricius and Hyalomma rufipes Koch for Congo virus, after intracoelomic inoculation. Vet. Parasitol. 1991, 38, 215–223.
  23. El-Azazy, O.M.; Scrimgeour, E.M. Crimean-Congo haemorrhagic fever virus infection in the western province of Saudi Arabia. Trans. R. Soc. Trop. Med. Hyg. 1997, 91, 275–278.
  24. Swanepoel, R.; Shepherd, A.J.; Leman, P.A.; Shepherd, S.P.; McGillivray, G.M.; Erasmus, M.J.; Searle, L.A.; Gill, D.E. Epidemiologic and clinical features of Crimean- Congo hemorrhagic fever in southern Africa. Am. J. Trop. Med. Hyg. 1987, 36, 120–132.
  25. Yen, Y.C.; Kong, L.X.; Lee, L.; Zhang, Y.Q.; Li, F.; Cai, B.J.; Gao, S.Y. Characteristics of Crimean-Congo hemorrhagic fever virus (Xinjiang strain) in China. Am. J. Trop. Med. Hyg. 1985, 34, 1179–1182.
  26. Gear, J.H.; Thomson, P.D.; Hopp, M.; Andronikou, S.; Cohn, R.J.; Ledger, J.; Berkowitz, F.E. Congo-Crimean haemorrhagic fever in South Africa. Report of a fatal case in the Transvaal. S. Afr. Med. J. 1982, 62, 576–580.
  27. Saluzzo, J.F.; Aubry, P.; McCormick, J.; Digoutte, J.P. Haemorrhagic fever caused by Crimean Congo haemorrhagic fever virus in Mauritania. Trans. R. Soc. Trop. Med. Hyg. 1985, 79, 268.
  28. Dunster, L.; Dunster, M.; Ofula, V.; Beti, D.; Kazooba-Voskamp, F.; Burt, F.; Swanepoel, R.; DeCock, K.M. First documentation of human Crimean-Congo hemorrhagic fever, Kenya. Emerg. Infect. Dis. 2002, 8, 1005–1006.
  29. Tantawi, H.H.; Al-Moslih, M.I.; Al-Janabi, N.Y.; Al-Bana, A.S.; Mahmud, M.I.; Jurji, F.; Yonan, M.S.; Al-Ani, F.; Al-Tikriti, S.K. Crimean-Congo haemorrhagic fever virus in Iraq: Isolation, identification and electron microscopy. Acta Virol. 1980, 24, 464–467.
  30. Schwarz, T.F.; Nitschko, H.; Jäger, G.; Nsanze, H.; Longson, M.; Pugh, R.N.; Abraham, A.K. Crimean-Congo haemorrhagic fever in Oman. Lancet 1995, 346, 1230.
  31. Chinikar, S.; Ghiasi, S.M.; Naddaf, S.; Piazak, N.; Moradi, M.; Razavi, M.R.; Afzali, N.; Haeri, A.; Mostafavizadeh, K.; Ataei, B.; et al. A serological survey in suspected human patients of Crimean-Congo hemorrhagic fever in Iran by determination of IgM-specific ELISA method during 2000–2004. Arch. Iran. Med. 2005, 8, 52–55.
  32. Mustafa, M.L.; Ayazi, E.; Mohareb, E.; Yingst, S.; Zayed, A.; Rossi, C.A.; Schoepp, R.J.; Mofleh, J.; Fiekert, K.; Akhbarian, Z.; et al. Crimean-Congo hemorrhagic fever, Afghanistan, 2009. Emerg. Infect. Dis. 2011, 17, 1940–1941.
  33. Burney, M.I.; Ghafoor, A.; Saleen, M.; Webb, P.A.; Casals, J. Nosocomial outbreak of viral hemorrhagic fever caused by Crimean hemorrhagic fever-Congo virus in Pakistan, January 1976. Am. J. Trop. Med. Hyg. 1980, 29, 941–947.
  34. Mishra, A.C.; Mehta, M.; Mourya, D.T.; Gandhi, S. Crimean-Congo haemorrhagic fever in India. Lancet 2011, 378, 372.
  35. Yadav, P.D.; Patil, D.Y.; Shete, A.M.; Kokate, P.; Goyal, P.; Jadhav, S.; Sinha, S.; Zawar, D.; Sharma, S.K.; Kapil, A.; et al. Nosocomial infection of CCHF among healthcare workers in Rajasthan, India. BMC Infect. Dis. 2016, 16, 624.
  36. Negredo, A.; de la Calle-Prieto, F.; Palencia-Herrejón, E.; Mora-Rillo, M.; Astray-Mochales, J.; Sánchez-Seco, M.P.; Bermejo Lopez, E.; Menárguez, J.; Fernández-Cruz, A.; Sánchez-Artola, B.; et al. Autochthonous Crimean-Congo hemorrhagic fever in Spain. N. Engl. J. Med. 2017, 377, 154–161.
  37. Papa, A.; Bino, S.; Llagami, A.; Brahimaj, B.; Papadimitriou, E.; Pavlidou, V.; Velo, E.; Cahani, G.; Hajdini, M.; Pilaca, A.; et al. Crimean-Congo hemorrhagic fever in Albania, 2001. Eur. J. Clin. Microbiol. Infect. Dis. 2002, 21, 603–606.
  38. Papa, A.; Christova, I.; Papadimitriou, E.; Antoniadis, A. Crimean-Congo hemorrhagic fever in Bulgaria. Emerg. Infect. Dis. 2004, 10, 1465–1467.
  39. Drosten, C.; Minnak, D.; Emmerich, P.; Schmitz, H.; Reinicke, T. Crimean-Congo hemorrhagic fever in Kosovo. J. Clin. Microbiol. 2002, 40, 1122–1123.
  40. Ceianu, C.S.; Panculescu-Gatej, R.I.; Coudrier, D.; Bouloy, M. First serologic evidence for the circulation of Crimean-Congo hemorrhagic fever virus in Romania. Vector Borne Zoonotic Dis. 2012, 12, 718–721.
  41. Karti, S.S.; Odabasi, Z.; Korten, V.; Yilmaz, M.; Sonmez, M.; Caylan, R.; Akdogan, E.; Eren, N.; Koksal, I.; Ovali, E.; et al. Crimean-Congo hemorrhagic fever in Turkey. Emerg. Infect. Dis. 2004, 10, 1379–1384.
  42. Tonbak, S.; Aktas, M.; Altay, K.; Azkur, A.K.; Kalkan, A.; Bolat, Y.; Dumanli, N.; Ozdarendeli, A. Crimean-Congo hemorrhagic fever virus: Genetic analysis and tick survey in Turkey. J. Clin. Microbiol. 2006, 44, 4120–4124.
  43. Yilmaz, G.R.; Buzgan, T.; Irmak, H.; Safran, A.; Uzun, R.; Cevik, M.A.; Torunoglu, M.A. The epidemiology of Crimean-Congo hemorrhagic fever in Turkey 2002–2007. Int. J. Infect. Dis. 2009, 13, 380–386.
  44. Midilli, K.; Gargili, A.; Ergonul, O.; Elevli, M.; Ergin, S.; Turan, N.; Sengöz, G.; Ozturk, R.; Bakar, M. The first clinical case due to AP92 like strain of Crimean-Congo Hemorrhagic Fever virus and a field survey. BMC Infect. Dis. 2009, 9, 90.
  45. Canakoglu, N.; Berber, E.; Ertek, M.; Yoruk, M.D.; Tonbak, S.; Bolat, Y.; Aktas, M.; Kalkan, A.; Ozdarendeli, A. Pseudo-Plaque Reduction Neutralization Test (PPRNT) for the Measurement of Neutralizing Antibodies to Crimean-Congo Hemorrhagic Fever Virus. Virol. J. 2013, 10, 6.
  46. European Centre for Disease Prevention and Control. Crimean-Congo Haemorrhagic Fever. In Annual Epidemiological Report for 2019; ECDC: Solna, Sweden, 2019. Available online: https://www.ecdc.europa.eu/en/publications-data/crimean-congo-haemorrhagic-fever-annual-epidemiological-report-2019 (accessed on 3 February 2021).
  47. Estrada-Pena, A.; Palomar, A.M.; Santibanez, P. Crimean-Congo Hemorrhagic Fever Virus in Ticks, Southwestern Europe, 2010. Emerg. Infect. Dis. 2012, 18, 179–180.
  48. Spengler, J.R.; Bergeron, E.; Spiropoulou, C.F. Crimean-Congo hemorrhagic fever and expansion from endemic regions. Curr. Opin. Virol. 2019, 34, 70–78.
  49. World Health Organization. Geographic Distribution of Crimean-Congo Haemorrhagic Fever. Available online: https://www.who.int/emergencies/diseases/crimean-congo-haemorrhagic-fever/Global_CCHFRisk_2017.jpg?ua=1 (accessed on 4 November 2019).
  50. Hoogstraal, H. The epidemiology of tick-borne Crimean-Congo hemorrhagic fever in Asia, Europe, and Africa. J. Med. Entomol. 1979, 15, 307–417.
  51. Jameson, L.J.; Morgan, P.J.; Medlock, J.M.; Watola, G.; Vaux, A.G.C. Importation of Hyalomma marginatum, vector of CrimeanCongo haemorrhagic fever virus, into the United Kingdom by migratory birds. Ticks Tick Borne Dis. 2012, 3, 95–99.
  52. Palomar, A.M.; Portillo, A.; Santibáñez, P. Crimean-Congo hemorrhagic fever virus in ticks from migratory birds, Morocco. Emerg. Infect. Dis. 2013, 19, 260–263.
  53. Capek, M.; Literak, I.; Kocianova, E.; Sychra, O.; Najer, T.; Trnka, A.; Kverek, P. Ticks of the Hyalomma marginatum complex transported by migratory birds into Central Europe. Ticks Tick Borne Dis. 2014, 5, 489–493.
  54. Estrada-Peña, A.; Venzal, J.M. Climate niches of tick species in the Mediterranean region: Modeling of occurrence data, distributional constraints, and impact of climate change. J. Med. Entomol. 2007, 44, 1130–1138.
  55. Vatansever, Z.; Uzun, R.; Estrada-Peña, A.; Ergonul, O. Crimean-Congo Hemorrhagic Fever: A Global Perspective, 1st ed.; Ergonul, O., Whitehouse, C.A., Eds.; Springer: Dordrecht, The Netherlands, 2007; pp. 59–74. ISBN 978-1-4020-6105-9.
  56. Estrada-Peña, A.; Sánchez, N.; Estrada-Sánchez, A. An assessment of the distribution and spread of the tick Hyalomma marginatum in the western Palearctic under different climate scenarios. Vector Borne Zoonotic Dis. 2012, 12, 758–768.
  57. Estrada-Peña, A.; Jameson, L.; Medlock, J.; Vatansever, Z.; Tishkova, F. Unraveling the ecological complexities of tickassociated Crimean-Congo hemorrhagic fever virus transmission: A gap analysis for the western Palearctic. Vector Borne Zoonotic Dis. 2012, 12, 743–752.
  58. Saleem, J.; Usman, M.; Nadeem, A.; Sethi, S.A.; Salman, M. Crimean-Congo hemorrhagic fever: A first case from Abbottabad, Pakistan. Int. J. Infect. Dis. 2009, 13, 121–123.
  59. Jameson, L.J.; Medlock, J.M. Results of HPA tick surveillance in Great Britain. Vet. Rec. 2009, 165, 154.
  60. Spengler, J.R.; Estrada-Peña, A.; Garrison, A.R.; Schmaljohn, C.; Spiropoulou, C.F.; Bergeron, E.; Bente, D. A chronological review of experimental infection studies on the role of wild animals and livestock in maintenance and transmission of Crimean-Congo hemorrhagic fever virus. Antivir. Res. 2016, 135, 31–47.
  61. Mallhi, T.H.; Khan, Y.H.; Sarriff, A.; Khan, A.H. Crimean-Congo haemorrhagic fever virus and Eid-Ul- Adha festival in Pakistan. Lancet Infect. Dis. 2016, 16, 1332–1333.
  62. Chisholm, K.; Dueger, E.; Fahmy, N.T.; Samaha, H.A.T.; Zayed, A.; Abdel-Dayem, M.; Villinski, J.T. Crimean-congo hemorrhagic fever virus in ticks from imported livestock, Egypt. Emerg. Infect. Dis. 2012, 18, 181–182.
  63. Çevik, M.A.; Erbay, A.; Bodur, H.; Gülderen, E.; Baştuğ, A.; Kubar, A. Clinical and laboratory features of CrimeanCongo hemorrhagic fever: Predictors of fatality. Int. J. Infect. Dis. 2008, 12, 374–382.
  64. Gürbüz, Y.; Sencan, I.; Oztürk, B.; Tütüncü, E. A case of nosocomial transmission of Crimean-Congo hemorrhagic fever from patient to patient. Int. J. Infect. Dis. 2009, 13, 105–111.
  65. Naderi, H.; Sheybani, F.; Bojdi, A.; Khosravi, N.; Mostafavi, I. Fatal nosocomial spread of Crimean-Congo hemorrhagic fever with very short incubation period. Am. J. Trop. Med. Hyg. 2013, 88, 469–539.
  66. Yildirmak, T.; Tulek, N.; Bulut, C. Crimean-Congo haemorrhagic fever: Transmission to visitors and healthcare workers. Infection 2016, 44, 687–695.
  67. Leblebicioglu, H.; Sunbul, M.; Guner, R.; Bodur, H.; Bulut, C.; Duygu, F. Healthcare-associated Crimean-Congo haemorrhagic fever in Turkey, 2002–2014: A multicentre retrospective cross-sectional study. Clin. Microbiol. Infect. 2016, 22, 387–390.
  68. Mehand, M.S.; Al-Shorbaji, F.; Millett, P.; Murgue, B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. Antivir. Res. 2018, 159, 63–67.
  69. Bente, D.A. Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antivir. Res. 2013, 100, 159–189.
  70. Rodriguez, S.E.; Hawman, D.W.; Sorvillo, T.E.; O’Neal, T.J.; Bird, B.H.; Rodriguez, L.L.; Bergeron, É.; Nichol, S.T.; Montgomery, J.M.; Spiropoulou, C.F.; et al. Immunobiology of Crimean-Congo hemorrhagic fever. Antivir. Res. 2022, 199, 105244.
  71. Hawman, D.W.; Feldmann, H. Crimean-Congo haemorrhagic fever virus. Nat. Rev. Microbiol. 2023, 14, 463–477.
  72. Andersson, I.; Lundkvist, A.; Haller, O.; Mirazimi, A. Type I interferon inhibits Crimean-Congo hemorrhagic fever virus in human target cells. J. Med. Virol. 2006, 78, 216–222.
  73. Hawman, D.W.; Meade-White, K.; Haddock, E.; Habib, R.; Scott, D.; Thomas, T.; Rosenke, R.; Feldmann, H. Crimean-Congo hemorrhagic fever mouse model recapitulating human convalescence. J. Virol. 2019, 93, 10–1128.
  74. Hawman, D.W.; Meade-White, K.; Leventhal, S.; Carmody, A.; Haddock, E.; Hasenkrug, K.; Feldmann, H. T- cells and interferon gamma are necessary for survival following Crimean-Congo hemorrhagic fever virus infection in mice. Microorganisms 2021, 9, 279.
  75. Bente, D.A.; Alimonti, J.B.; Shieh, W.-J.; Camus, G.; Ströher, U.; Zaki, S.; Jones, S.M. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. J. Virol. 2010, 84, 11089–11100.
  76. Bereczky, S.; Lindegren, G.; Karlberg, H. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor- knockout mice. J. Gen. Virol. 2010, 91, 1473–1477.
  77. Lindquist, M.E.; Zeng, X.; Altamura, L.A.; Daye, S.P.; Delp, K.L.; Blancett, C.; Coffin, K.M.; Koehler, J.W.; Coyne, S.; Shoemaker, C.J.; et al. Exploring Crimean-Congo hemorrhagic fever virus-induced hepatic injury using antibody-mediated type I interferon blockade in mice. J. Virol. 2018, 92, e01083-18.
  78. Arslan, S.; Engin, A.; Ozbilüm, N.; Bakır, M. Toll-like receptor 7 Gln11Leu, c.4- 151A/G, and +1817G/Tpolymorphisms in Crimean-Congo hemorrhagic fever. J. Med. Virol. 2015, 87, 1090–1095.
  79. Engin, A.; Arslan, S.; Özbilüm, N.; Bakir, M. Is there any relationship between Toll-like receptor 3 c.1377C/Tand -7C/A polymorphisms and susceptibility to Crimean Congo hemorrhagic fever? J. Med. Virol. 2016, 88, 1690–1696.
  80. Weber, F.; Mirazimi, A. Interferon and cytokine responses to Crimean Congo hemorrhagic fever virus; an emerging and neglected viral zonoosis. Cytokine Growth Factor. Rev. 2008, 19, 395–404.
  81. Habjan, M.; Andersson, I.; Klingström, J.; Schümann, M.; Martin, A.; Zimmermann, P.; Wagner, V.; Pichlmair, A.; Schneider, U.; Mühlberger, E.; et al. Processing of genome 51 termini as a strategy of negative-strand RNA viruses to avoid RIG-I-dependent interferon induction. PLoS ONE 2008, 3, e2032.
  82. Spengler, J.R.; Patel, J.R.; Chakrabarti, A.K.; Zivcec, M.; García-Sastre, A.; Spiropoulou, C.F.; Bergeron, E. RIG-I mediates an antiviral response to Crimean-Congo hemorrhagic fever virus. J. Virol. 2015, 89, 10119–10229.
  83. Zivcec, M.; Metcalfe, M.G.; Albariño, C.G.; Guerrero, L.W.; Pegan, S.D.; Spiropoulou, C.F.; Bergeron, É. Assessment of inhibitors of pathogenic Crimean-Congo hemorrhagic fever virus strains using virus-like particles. PLoS Negl. Trop. Dis. 2015, 9, e0004259.
  84. Everett, H.; McFadden, G. Apoptosis: An innate immune response to virus infection. Trends Microbiol. 1999, 7, 160–165.
  85. Barber, G. Host defense, viruses and apoptosis. Cell Death Differ. 2001, 8, 113–126.
  86. Karlberg, H.; Tan, Y.J.; Mirazimi, A. Crimean–Congo haemorrhagic fever replication interplays with regulation mechanisms of apoptosis. J. Gen. Virol. 2015, 96, 538–546.
  87. Rodrigues, R.; Paranhos-Baccalà, G.; Vernet, G.; Peyrefitte, C.N. Crimean-Congo hemorrhagic fever virus-infected hepatocytes induce ER-stress and apoptosis crosstalk. PLoS ONE 2012, 7, 29712.
  88. Barnwal, B.; Karlberg, H.; Mirazimi, A.; Tan, Y.J. The Non-structural Protein of Crimean-Congo Hemorrhagic Fever Virus Disrupts the Mitochondrial Membrane Potential and Induces Apoptosis. J. Biol. Chem. 2016, 291, 582–592.
  89. Li, D.; Wu, M. Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 2021, 6, 291.
  90. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors. Nat. Immunol. 2010, 11, 373–384.
  91. Mogensen, T.H. Pathogen recognition and inflammatory signaling in innate immune defenses. Clin. Microbiol. Rev. 2009, 22, 240–273.
  92. Newton, K.; Dixit, V.M. Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol. 2012, 4, a006049.
  93. Connolly-Andersen, A.M.; Douagi, I.; Kraus, A.A.; Mirazimi, A. Crimean Congo hemorrhagic fever virus infects human monocyte-derived dendritic cells. Virology 2009, 390, 157–162.
  94. Ergönül, Ö.; Şeref, C.; Eren, Ş.; Çelikbaş, A.; Baykam, N.; Dokuzoğuz, B.; Gönen, M.; Can, F. Cytokine response in crimean-congo hemorrhagic fever virus infection. J. Med. Virol. 2017, 89, 1707–1713.
  95. Saksida, A.; Duh, D.; Wraber, B.; Dedushaj, I.; Ahmeti, S.; Avsic-Zupanc, T. Interacting roles of immune mechanisms and viral load in the pathogenesis of crimean-congo hemorrhagic fever. Clin. Vaccine Immunol. 2010, 17, 1086–1093.
  96. Papa, A.; Bino, S.; Velo, E.; Harxhi, A.; Kota, M.; Antoniadis, A. Cytokine levels in Crimean-Congo hemorrhagic fever. J. Clin. Virol. 2006, 36, 272–276.
  97. Papa, A.; Tsergouli, K.; Çağlayık, D.Y.; Bino, S.; Como, N.; Uyar, Y.; Korukluoglu, G. Cytokines as biomarkers of Crimean-Congo hemorrhagic fever. J. Med. Virol. 2016, 88, 21–27.
  98. Altay, F.A.; Elaldi, N.; Şentürk, G.Ç.; Altin, N.; Gözel, M.G.; Albayrak, Y.; Şencan, İ. Serum sTREM-1 level is quite higher in Crimean Congo Hemorrhagic Fever, a viral infection. J. Med. Virol. 2016, 88, 1473–1478.
  99. Hamidinejad, M.A.; Esmaeili Gouvarchin Ghaleh, H.; Farzanehpour, M.; Bolandian, M.; Dorostkar, R. Crimean-Congo hemorrhagic fever from the immunopathogenesis, clinical, diagnostic, and therapeutic perspective: A scoping review. Asian Pac. J. Trop. Med. 2021, 14, 254–265.
  100. Shepherd, A.J.; Swanepoel, R.; Leman, P.A. Antibody response in Crimean-Congo hemorrhagic fever. Rev. Infect. Dis. 1989, 11, S801–S806.
  101. Burt, F.J.; Leman, P.A.; Abbott, J.C.; Swanepoel, R. Serodiagnosis of Crimean-Congo haemorrhagic fever. Epidemiol. Infect. 1994, 113, 551–562.
  102. Ergunay, K.; Kocak Tufan, Z.; Bulut, C.; Kinikli, S.; Demiroz, A.P.; Ozkul, A. Antibody responses and viral load in patients with Crimean-Congo hemorrhagic fever: A comprehensive analysis during the early stages of the infection. Diagn. Microbiol. Infect. Dis. 2014, 79, 31–36.
  103. Kaya, S.; Elaldi, N.; Kubar, A.; Gursoy, N.; Yilmaz, M.; Karakus, G.; Gunes, T.; Polat, Z.; Gozel, M.G.; Engin, A.; et al. Sequential determination of serum viral titers, virus-specific IgG antibodies, and TNF-α, IL-6, IL-10, and IFN-γ levels in patients with Crimean-Congo hemorrhagic fever. BMC Infect. Dis. 2014, 14, 416.
  104. Duh, D.; Saksida, A.; Petrovec, M.; Ahmeti, S.; Dedushaj, I.; Panning, M.; Drosten, C.; Avsic-Zupanc, T. Viral load as predictor of Crimean-Congo hemorrhagic fever outcome. Emerg. Infect. Dis. 2007, 13, 1769–1772.
  105. Bertolotti-Ciarlet, A.; Smith, J.; Strecker, K.; Paragas, J.; Altamura, L.A.; McFalls, J.M.; Frias-Stäheli, N.; García-Sastre, A.; Schmaljohn, C.S.; Doms, R.W. Cellular localization and antigenic characterization of crimean-congo hemorrhagic fever virus glycoproteins. J. Virol. 2005, 79, 6152–6161.
  106. Zivcec, M.; Guerrero, L.I.W.; Albariño, C.G.; Bergeron, É.; Nichol, S.T.; Spiropoulou, C.F. Identification of broadly neutralizing monoclonal antibodies against Crimean-Congo hemorrhagic fever virus. Antivir. Res. 2017, 146, 112–120.
  107. Golden, J.W.; Shoemaker, C.J.; Lindquist, M.E.; Zeng, X.; Daye, S.P.; Williams, J.A.; Liu, J.; Coffin, K.M.; Olschner, S.; Flusin, O.; et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. Sci. Adv. 2019, 5, eaaw9535.
  108. Mishra, A.K.; Moyer, C.L.; Abelson, D.M.; Deer, D.J.; ElOmari, K.; Duman, R.; Lobel, L.; Lutwama, J.J.; Dye, J.M.; Wagner, A.; et al. Structure and Characterization of Crimean-Congo Hemorrhagic Fever Virus GP38. J. Virol. 2020, 94, e02005-19.
  109. Fels, J.M.; Maurer, D.P.; Herbert, A.S.; Wirchnianski, A.S.; Vergnolle, O.; Cross, R.W.; Abelson, D.M.; Moyer, C.L.; Mishra, A.K.; Aguilan, J.T.; et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. Cell 2021, 184, 3486–3501.e21.
  110. Hasanoglu, I.; Guner, R.; Carhan, A.; Kocak Tufan, Z.; Yagci-Caglayik, D.; Guven, T.; Yilmaz, G.R.; Tasyaran, M.A. Crucial parameter of the outcome in Crimean Congo hemorrhagic fever: Viral load. J. Clin. Virol. 2016, 75, 42–46.
  111. Hawman, D.W.; Meade-White, K.; Leventhal, S.; Feldmann, F.; Okumura, A.; Smith, B.; Scott, D.; Feldmann, H. Immunocompetent mouse model for Crimean-Congo hemorrhagic fever virus. eLife 2021, 10, e63906.
  112. Hinkula, J.; Devignot, S.; Åkerström, S.; Karlberg, H.; Wattrang, E.; Bereczky, S.; MousaviJazi, M.; Risinger, C.; Lindegren, G.; Vernersson, C.; et al. Immunization with DNA Plasmids Coding for Crimean-Congo Hemorrhagic Fever Virus Capsid and Envelope Proteins and/or Virus-Like Particles Induces Protection and Survival in Challenged Mice. J. Virol. 2017, 91, e02076-16.
  113. Goedhals, D.; Paweska, J.T.; Burt, F.J. Long-lived CD8+ T cell responses following Crimean-Congo haemorrhagic fever virus infection. PLoS Negl. Trop. Dis. 2017, 11, e0006149.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Microbiology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Aykut Ozdarendeli
View Times: 473
Revisions: 2 times (View History)
Update Date: 08 Oct 2023
Table of Contents
    1000/1000
    Hot Most Recent
    ScholarVision Creations
    Feedback